OncoMatch/Clinical Trials/NCT07011004
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
Is NCT07011004 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Cytokine Induced Memory-Like Natural Killer Cells and Atezolizumb for acute myeloid leukemia refractory.
Treatment: Cytokine Induced Memory-Like Natural Killer Cells · Atezolizumb · CIML-NK cell therapy — The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with relapsed/refractory acute myelogenous leukemia (AML). The researchers will also look at whether the treatment combination works against participants' cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Allowed: FLT3 ITD mutation
Patients with FLT3-ITD or -TKD mutations must have received at least one commercially available inhibitor of FLT3.
Allowed: FLT3 TKD mutation
Patients with FLT3-ITD or -TKD mutations must have received at least one commercially available inhibitor of FLT3.
Allowed: NPM1 mutation
Patients with NPM1 mutation or rearrangements of MLL must be refractory to revumenib.
Allowed: KMT2A (MLL) rearrangement
Patients with NPM1 mutation or rearrangements of MLL must be refractory to revumenib.
Allowed: IDH1 mutation
Patients with mutations in IDH1 or IDH2 must be refractory to at least one commercially available inhibitor of IDH1 or IDH2, respectively.
Allowed: IDH2 mutation
Patients with mutations in IDH1 or IDH2 must be refractory to at least one commercially available inhibitor of IDH1 or IDH2, respectively.
Prior therapy
Must have received: combination chemotherapy (daunorubicin, anthracycline) — induction
Refractory to at least two attempts at prior induction therapy. An attempt is defined as either a single cycle of combination chemotherapy such as daunorubicin/anthracycline
Must have received: hypomethylating agent with venetoclax (hypomethylating agent, venetoclax) — induction
A single monthly cycle of a hypomethylating agent with venetoclax
Must have received: FLT3 inhibitor
Patients with FLT3-ITD or -TKD mutations must have received at least one commercially available inhibitor of FLT3.
Must have received: revumenib (revumenib)
Patients with NPM1 mutation or rearrangements of MLL must be refractory to revumenib.
Must have received: IDH1 inhibitor
Patients with mutations in IDH1 or IDH2 must be refractory to at least one commercially available inhibitor of IDH1 or IDH2, respectively.
Must have received: IDH2 inhibitor
Patients with mutations in IDH1 or IDH2 must be refractory to at least one commercially available inhibitor of IDH1 or IDH2, respectively.
Cannot have received: allogeneic hematopoietic cell transplantation
Prior allogeneic hematopoietic cell transplantation
Lab requirements
Kidney function
estimated or measured creatinine clearance > 50 ml/min
Liver function
serum bilirubin ≤ 5 mg/dl; ast and alt ≤ 2.5x uln unless thought to be disease related
Cardiac function
systolic lv ejection fraction ≥50% at rest and absence of new york heart association stage iii or iv congestive heart failure
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities) · Commack, New York
- Memorial Sloan Kettering West Harrison (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify